Showing results (31-40 of 48) with videos related to

Sort By:
Pageof 5
Blood|October 6, 2018
The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLLIan W Flinn, Peter Hillmen, Marco Montillo, et al.
Haematologica|October 19, 2023
Outcomes of limited stage primary bone diffuse large B-cell lymphoma in the rituximab era: a multicenter, retrospective studyAlexandra Rezazadeh, Aniko Szabo, Arushi Khurana, et al.
Blood Advances|August 27, 2021
Multicenter analysis of geriatric fitness and real-world outcomes in older patients with classical Hodgkin lymphomaVictor M Orellana-Noia, Krista Isaac, Mary-Kate Malecek, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 16, 2021
The MAGNOLIA Trial: Zanubrutinib, a Next-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone LymphomaStephen Opat, Alessandra Tedeschi, Kim Linton, et al.
American Journal of Hematology|January 2, 2023
Outcomes of patients with limited-stage plasmablastic lymphoma: A multi-institutional retrospective studyBrian T Hess, Anshu Giri, Yeonhee Park, et al.
British Journal of Haematology|December 22, 2018
Maintenance rituximab or observation after frontline treatment with bendamustine-rituximab for follicular lymphomaBrian T Hill, Loretta Nastoupil, Allison M Winter, et al.
The New England Journal of Medicine|June 20, 2024
Combination Targeted Therapy in Relapsed Diffuse Large B-Cell LymphomaChristopher Melani, Rahul Lakhotia, Stefania Pittaluga, et al.
Cancer|October 1, 2019
Outcomes in patients with aggressive B-cell non-Hodgkin lymphoma after intensive frontline treatment failureEmily C Ayers, Shaoying Li, L Jeffrey Medeiros, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 27, 2021
Burkitt Lymphoma International Prognostic IndexAdam J Olszewski, Lasse H Jakobsen, Graham P Collins, et al.
Blood|September 27, 2021
Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutionsVictor Manuel Orellana-Noia, Daniel R Reed, Ashley Alesia McCook, et al.
Pageof 5